...
cmpx-img

Compass Therapeutics Inc., Common Stock

CMPX

NAQ

$1.42

-$0.11

(-7.19%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$210.51M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
421.31K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.75
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.77 L
$2.34 H
$1.42

About Compass Therapeutics Inc., Common Stock

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameCMPXSectorS&P500
1-Week Return-14.97%-2.06%-0.55%
1-Month Return5.19%-1.92%2.72%
3-Month Return-12.88%-10.4%7.66%
6-Month Return26.79%-4.6%10.15%
1-Year Return-10.13%4.06%27.53%
3-Year Return-53.9%1.94%32.31%
5-Year Return-83.29%36.48%89.2%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue2.12M2.40M1.62M1.90M1.89M[{"date":"2019-12-31","value":88.19,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":67.55,"profit":true},{"date":"2022-12-31","value":79.2,"profit":true},{"date":"2023-12-31","value":78.62,"profit":true}]
Gross Profit(2.12M)(2.40M)(1.62M)(1.90M)(1.89M)[{"date":"2019-12-31","value":-212000000,"profit":false},{"date":"2020-12-31","value":-240400000,"profit":false},{"date":"2021-12-31","value":-162400000,"profit":false},{"date":"2022-12-31","value":-190400000,"profit":false},{"date":"2023-12-31","value":-189000000,"profit":false}]
Gross Margin-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Operating Expenses34.05M27.81M31.26M41.66M48.47M[{"date":"2019-12-31","value":70.25,"profit":true},{"date":"2020-12-31","value":57.38,"profit":true},{"date":"2021-12-31","value":64.5,"profit":true},{"date":"2022-12-31","value":85.93,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(34.05M)(27.81M)(81.88M)(41.66M)(50.36M)[{"date":"2019-12-31","value":-3405200000,"profit":false},{"date":"2020-12-31","value":-2781200000,"profit":false},{"date":"2021-12-31","value":-8188200000,"profit":false},{"date":"2022-12-31","value":-4165500000,"profit":false},{"date":"2023-12-31","value":-5036300000,"profit":false}]
Total Non-Operating Income/Expense(1.09M)(2.48M)(640.00K)4.79M15.74M[{"date":"2019-12-31","value":-6.9,"profit":false},{"date":"2020-12-31","value":-15.73,"profit":false},{"date":"2021-12-31","value":-4.07,"profit":false},{"date":"2022-12-31","value":30.44,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(34.65M)(29.47M)(82.18M)(39.23M)(42.49M)[{"date":"2019-12-31","value":-3465300000,"profit":false},{"date":"2020-12-31","value":-2946800000,"profit":false},{"date":"2021-12-31","value":-8218100000,"profit":false},{"date":"2022-12-31","value":-3922500000,"profit":false},{"date":"2023-12-31","value":-4249400000,"profit":false}]
Income Taxes91.00K32.00K370.00K(2.43M)-[{"date":"2019-12-31","value":24.59,"profit":true},{"date":"2020-12-31","value":8.65,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-656.76,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Income After Taxes(34.74M)(29.50M)(82.55M)(36.80M)-[{"date":"2019-12-31","value":-3474400000,"profit":false},{"date":"2020-12-31","value":-2950000000,"profit":false},{"date":"2021-12-31","value":-8255100000,"profit":false},{"date":"2022-12-31","value":-3679500000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Income From Continuous Operations(34.74M)(29.50M)(82.18M)(39.23M)(42.49M)[{"date":"2019-12-31","value":-3474400000,"profit":false},{"date":"2020-12-31","value":-2950000000,"profit":false},{"date":"2021-12-31","value":-8218100000,"profit":false},{"date":"2022-12-31","value":-3922500000,"profit":false},{"date":"2023-12-31","value":-4249400000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(34.74M)(29.50M)(82.55M)(36.80M)(42.49M)[{"date":"2019-12-31","value":-3474400000,"profit":false},{"date":"2020-12-31","value":-2950000000,"profit":false},{"date":"2021-12-31","value":-8255100000,"profit":false},{"date":"2022-12-31","value":-3679500000,"profit":false},{"date":"2023-12-31","value":-4249400000,"profit":false}]
EPS (Diluted)(4.45)(0.93)(1.52)(0.37)(0.34)[{"date":"2019-12-31","value":-444.74,"profit":false},{"date":"2020-12-31","value":-92.81,"profit":false},{"date":"2021-12-31","value":-152,"profit":false},{"date":"2022-12-31","value":-37,"profit":false},{"date":"2023-12-31","value":-34,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

CMPX
Cash Ratio 30.54
Current Ratio 31.84

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

CMPX
ROA (LTM) -21.71%
ROE (LTM) -32.00%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

CMPX
Debt Ratio Lower is generally better. Negative is bad. 0.07
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.93

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

CMPX
Trailing PE NM
Forward PE NM
P/S (TTM) 247.66
P/B 1.52
Price/FCF NM
EV/R 96.45
EV/Ebitda NM

FAQs

What is Compass Therapeutics Inc. share price today?

Compass Therapeutics Inc. (CMPX) share price today is $1.42

Can Indians buy Compass Therapeutics Inc. shares?

Yes, Indians can buy shares of Compass Therapeutics Inc. (CMPX) on Vested. To buy Compass Therapeutics Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CMPX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Compass Therapeutics Inc. be purchased?

Yes, you can purchase fractional shares of Compass Therapeutics Inc. (CMPX) via the Vested app. You can start investing in Compass Therapeutics Inc. (CMPX) with a minimum investment of $1.

How to invest in Compass Therapeutics Inc. shares from India?

You can invest in shares of Compass Therapeutics Inc. (CMPX) via Vested in three simple steps:

  • Click on Sign Up or Invest in CMPX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Compass Therapeutics Inc. shares
What is Compass Therapeutics Inc. 52-week high and low stock price?

The 52-week high price of Compass Therapeutics Inc. (CMPX) is $2.34. The 52-week low price of Compass Therapeutics Inc. (CMPX) is $0.77.

What is Compass Therapeutics Inc. price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Compass Therapeutics Inc. (CMPX) is

What is Compass Therapeutics Inc. price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Compass Therapeutics Inc. (CMPX) is 1.52

What is Compass Therapeutics Inc. dividend yield?

The dividend yield of Compass Therapeutics Inc. (CMPX) is 0.00%

What is the Market Cap of Compass Therapeutics Inc.?

The market capitalization of Compass Therapeutics Inc. (CMPX) is $210.51M

What is Compass Therapeutics Inc.’s stock symbol?

The stock symbol (or ticker) of Compass Therapeutics Inc. is CMPX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top